456
H. Jin
151. Zhou W, Xu F, Li D, Chen Y (2018) Improved detection of HER2 by a quasi-targeted
proteomics approach using aptamer-peptide probe and liquid chromatography-tandem mass
spectrometry. Clin Chem 64(3):526–535. https://doi.org/10.1373/clinchem.2017.274266
152. Heo D, Ku M, Kim JH, Yang J, Suh JS (2018) Aptamer-modified magnetic nanosensitizer for
in vivo MR imaging of HER2-expressing cancer. Nanoscale Res Lett 13(1):288. https://doi.
org/10.1186/s11671-018-2682-3
153. Kim HJ, Park JY, Lee TS, Song IH, Cho YL, Chae JR, Kang H, Lim JH, Lee JH, Kang WJ
(2019) PET imaging of HER2 expression with an 18F-fluoride labeled aptamer. PLoS ONE
14(1):e0211047. https://doi.org/10.1371/journal.pone.0211047
154. Tan Y, Peng Y, Ai L, Li Y, Qu YX, Wang D, Su Y, Deng T, Fu T, Zhao Z, Wang XQ,
Tan W (2020) Aptamer enables consistent maytansine delivery through maintaining receptor
homeostasis for HER2 targeted cancer therapy. Bioconjug Chem 31(7):1766–1774. https://
doi.org/10.1021/acs.bioconjchem.0c00250
155. Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA (2015) The 2014 society of
surgical oncology Susan G. Komen for the cure symposium: triple-negative breast cancer.
Ann Surg Oncol 22(3):874–882. https://doi.org/10.1245/s10434-014-4279-0
156. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and
progression. Nature 432(7015):332–337. https://doi.org/10.1038/nature03096
157. Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese
S, Lucarelli E, Cerchia L, Zannetti A (2017) Inhibition of bone marrow-derived mesenchymal
stem cells homing towards triple-negative breast cancer microenvironment using an AntiPDGFRβ aptamer. Theranostics 7(14):3595–3607. https://doi.org/10.7150/thno.18974
158. Kuzmanov A, Hopfer U, Marti P, Meyer-Schaller N, Yilmaz M, Christofori G (2014) LIMhomeobox gene 2 promotes tumor growth and metastasis by inducing autocrine and paracrine
PDGF-B signaling. Mol Oncol 8(2):401–416. https://doi.org/10.1016/j.molonc.2013.12.009
159. Meng F, Speyer CL, Zhang B, Zhao Y, Chen W, Gorski DH, Miller FR, Wu G (2015)
PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness
and chemoresistance. Cancer Res 75(3):584–593. https://doi.org/10.1158/0008-5472.Can13-3029
160. D’Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni
AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio
MV (2016) miR-9 and miR-200 regulate PDGFRβ-Mediated endothelial differentiation of
tumor cells in Triple-Negative breast cancer. Cancer Res 76(18):5562–5572. https://doi.org/
10.1158/0008-5472.Can-16-0140
161. Camorani S, Hill BS, Collina F, Gargiulo S, Napolitano M, Cantile M, Di Bonito M, Botti G,
Fedele M, Zannetti A, Cerchia L (2018) Targeted imaging and inhibition of triple-negative
breast cancer metastases by a PDGFRβ aptamer. Theranostics 8(18):5178–5199. https://doi.
org/10.7150/thno.27798
162. Jing X, Liang H, Hao C, Yang X, Cui X (2019) Overexpression of MUC1 predicts poor
prognosis in patients with breast cancer. Oncol Rep 41(2):801–810. https://doi.org/10.3892/
or.2018.6887
163. Ferreira CS, Cheung MC, Missailidis S, Bisland S, Gariépy J (2009) Phototoxic aptamers
selectively enter and kill epithelial cancer cells. Nucl Acids Res 37(3):866–876. https://doi.
org/10.1093/nar/gkn967
164. Luo S, Wang S, Luo N, Chen F, Hu C, Zhang K (2018) The application of aptamer 5TR1 in
triple negative breast cancer target therapy. J Cell Biochem 119(1):896–908
165. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a
molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18(4):260–267.
https://doi.org/10.1016/j.semcancer.2008.03.015
166. Zöller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed
molecule? Nat Rev Cancer 11(4):254–267. https://doi.org/10.1038/nrc3023
167. Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, Lin C, Zhan Q, Qian H, Xu B (2014) Enriched
CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative
breast cancer (TNBC). Cancer Lett 353(2):153–159. https://doi.org/10.1016/j.canlet.2014.
06.022
H. Jin
151. Zhou W, Xu F, Li D, Chen Y (2018) Improved detection of HER2 by a quasi-targeted
proteomics approach using aptamer-peptide probe and liquid chromatography-tandem mass
spectrometry. Clin Chem 64(3):526–535. https://doi.org/10.1373/clinchem.2017.274266
152. Heo D, Ku M, Kim JH, Yang J, Suh JS (2018) Aptamer-modified magnetic nanosensitizer for
in vivo MR imaging of HER2-expressing cancer. Nanoscale Res Lett 13(1):288. https://doi.
org/10.1186/s11671-018-2682-3
153. Kim HJ, Park JY, Lee TS, Song IH, Cho YL, Chae JR, Kang H, Lim JH, Lee JH, Kang WJ
(2019) PET imaging of HER2 expression with an 18F-fluoride labeled aptamer. PLoS ONE
14(1):e0211047. https://doi.org/10.1371/journal.pone.0211047
154. Tan Y, Peng Y, Ai L, Li Y, Qu YX, Wang D, Su Y, Deng T, Fu T, Zhao Z, Wang XQ,
Tan W (2020) Aptamer enables consistent maytansine delivery through maintaining receptor
homeostasis for HER2 targeted cancer therapy. Bioconjug Chem 31(7):1766–1774. https://
doi.org/10.1021/acs.bioconjchem.0c00250
155. Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA (2015) The 2014 society of
surgical oncology Susan G. Komen for the cure symposium: triple-negative breast cancer.
Ann Surg Oncol 22(3):874–882. https://doi.org/10.1245/s10434-014-4279-0
156. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and
progression. Nature 432(7015):332–337. https://doi.org/10.1038/nature03096
157. Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese
S, Lucarelli E, Cerchia L, Zannetti A (2017) Inhibition of bone marrow-derived mesenchymal
stem cells homing towards triple-negative breast cancer microenvironment using an AntiPDGFRβ aptamer. Theranostics 7(14):3595–3607. https://doi.org/10.7150/thno.18974
158. Kuzmanov A, Hopfer U, Marti P, Meyer-Schaller N, Yilmaz M, Christofori G (2014) LIMhomeobox gene 2 promotes tumor growth and metastasis by inducing autocrine and paracrine
PDGF-B signaling. Mol Oncol 8(2):401–416. https://doi.org/10.1016/j.molonc.2013.12.009
159. Meng F, Speyer CL, Zhang B, Zhao Y, Chen W, Gorski DH, Miller FR, Wu G (2015)
PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness
and chemoresistance. Cancer Res 75(3):584–593. https://doi.org/10.1158/0008-5472.Can13-3029
160. D’Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni
AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio
MV (2016) miR-9 and miR-200 regulate PDGFRβ-Mediated endothelial differentiation of
tumor cells in Triple-Negative breast cancer. Cancer Res 76(18):5562–5572. https://doi.org/
10.1158/0008-5472.Can-16-0140
161. Camorani S, Hill BS, Collina F, Gargiulo S, Napolitano M, Cantile M, Di Bonito M, Botti G,
Fedele M, Zannetti A, Cerchia L (2018) Targeted imaging and inhibition of triple-negative
breast cancer metastases by a PDGFRβ aptamer. Theranostics 8(18):5178–5199. https://doi.
org/10.7150/thno.27798
162. Jing X, Liang H, Hao C, Yang X, Cui X (2019) Overexpression of MUC1 predicts poor
prognosis in patients with breast cancer. Oncol Rep 41(2):801–810. https://doi.org/10.3892/
or.2018.6887
163. Ferreira CS, Cheung MC, Missailidis S, Bisland S, Gariépy J (2009) Phototoxic aptamers
selectively enter and kill epithelial cancer cells. Nucl Acids Res 37(3):866–876. https://doi.
org/10.1093/nar/gkn967
164. Luo S, Wang S, Luo N, Chen F, Hu C, Zhang K (2018) The application of aptamer 5TR1 in
triple negative breast cancer target therapy. J Cell Biochem 119(1):896–908
165. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a
molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18(4):260–267.
https://doi.org/10.1016/j.semcancer.2008.03.015
166. Zöller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed
molecule? Nat Rev Cancer 11(4):254–267. https://doi.org/10.1038/nrc3023
167. Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, Lin C, Zhan Q, Qian H, Xu B (2014) Enriched
CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative
breast cancer (TNBC). Cancer Lett 353(2):153–159. https://doi.org/10.1016/j.canlet.2014.
06.022